A Phase II, Open-label, Platform Study, to Evaluate Immunotherapy-based Combinations in Participants With Advanced Non–Small Cell Lung Cancer
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: Zimberelimab, Domvanalimab, Quemliclustat, Chemotherapy
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Giuseppe lo russo
The study presents several sub-studies:
Substudy A, which will evaluate zimberelimab in combination with domvanalimab and quemliclustat in participants with elevated PDL1 greater than 50%.
Substudy B, which will evaluate zimberelimab in combination with chemotherapy, quemliclustat and domvanalimab regardless of PDL1 value.
Last update: 20/05/2025